Short Interest in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Increases By 151.6%

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 4,000,000 shares, a growth of 151.6% from the November 30th total of 1,590,000 shares. Based on an average daily trading volume, of 93,440,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.1% of the company’s stock are sold short.

Tonix Pharmaceuticals Stock Down 8.8 %

Shares of Tonix Pharmaceuticals stock traded down $0.03 during trading on Friday, hitting $0.34. 73,979,242 shares of the stock were exchanged, compared to its average volume of 30,416,361. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The firm’s 50-day moving average price is $0.22 and its 200 day moving average price is $0.38. The stock has a market cap of $63.10 million, a price-to-earnings ratio of -0.01 and a beta of 2.23. Tonix Pharmaceuticals has a 12-month low of $0.12 and a 12-month high of $14.08.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The company had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. As a group, analysts forecast that Tonix Pharmaceuticals will post -17.63 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a research report on Monday, December 23rd. They set a “hold” rating for the company.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.